February 14, 2018 / 2:19 PM / 10 months ago

BRIEF-Sienna Biopharma Announces First Patient Dosed In First-In-Human Trial Of Topical SNA-125

Feb 14 (Reuters) - Sienna Biopharmaceuticals Inc:

* SIENNA BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN FIRST-IN-HUMAN TRIAL OF TOPICAL SNA-125

* SIENNA BIOPHARMACEUTICALS INC - TOP-LINE RESULTS FROM STUDY EXPECTED IN Q3 OF 2018

* SIENNA BIOPHARMACEUTICALS INC - PLAN TO INITIATE SNA-125 PROOF-OF-CONCEPT TRIAL FOR ATOPIC DERMATITIS AND EXPECT THOSE DATA IN SECOND HALF OF 2018

* SIENNA BIOPHARMACEUTICALS- EXPECT TO REPORT TOP-LINE DATA IN 1H 2019 FROM SNA-120 PHASE 2B CLINICAL TRIAL FOR PRURITUS & ASSOCIATED UNDERLYING PSORIASIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below